Tonix Pharmaceuticals Holding Corp. Daily Stock Analysis

Daily Stock Analysis, TNXP, Tonix Pharmaceuticals Holding Corp, priceseries

Tonix Pharmaceuticals Holding Corp. Daily Stock Analysis
Stock Information
Open
0.22
Close
0.20
High
0.22
Low
0.20
Previous Close
0.21
Daily Price Gain
-0.01
YTD High
0.43
YTD High Date
Jan 4, 2022
YTD Low
0.15
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.20
YTD Gain
-49.98%
52 Week High
1.59
52 Week High Date
Mar 17, 2021
52 Week Low
0.15
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-0.82
52 Week Gain
-80.38%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
510.00
Jan 11. 2017
540.52
6 Trading Days
5.99%
Link
LONG
Aug 22. 2017
321.00
Sep 14. 2017
395.98
16 Trading Days
23.36%
Link
LONG
Oct 3. 2017
438.00
Oct 12. 2017
462.39
7 Trading Days
5.57%
Link
LONG
Nov 17. 2017
362.00
Dec 1. 2017
384.73
9 Trading Days
6.28%
Link
LONG
Jun 4. 2018
336.00
Jun 14. 2018
396.14
8 Trading Days
17.90%
Link
LONG
Oct 3. 2018
69.50
Oct 4. 2018
81.25
1 Trading Days
16.91%
Link
LONG
Mar 7. 2019
21.40
Mar 19. 2019
26.92
8 Trading Days
25.80%
Link
LONG
May 22. 2019
20.30
May 23. 2019
22.60
1 Trading Days
11.33%
Link
LONG
Oct 2. 2019
4.30
Oct 3. 2019
4.60
1 Trading Days
6.96%
Link
LONG
Dec 30. 2019
1.14
Jan 13. 2020
1.46
9 Trading Days
28.21%
Link
LONG
Feb 26. 2020
0.90
Mar 4. 2020
1.02
5 Trading Days
12.78%
Link
LONG
Jul 16. 2020
0.64
Jul 28. 2020
1.11
8 Trading Days
74.78%
Link
LONG
Jul 30. 2020
1.34
Jul 31. 2020
1.43
1 Trading Days
6.72%
Link
LONG
Feb 2. 2021
1.05
Feb 18. 2021
1.51
11 Trading Days
44.08%
Link
LONG
May 27. 2021
1.18
Jun 16. 2021
1.27
13 Trading Days
7.61%
Link
Company Information
Stock Symbol
TNXP
Exchange
NasdaqGM
Company URL
http://www.tonixpharma.com
Company Phone
1-800-849-7894
CEO
Seth Lederman
Headquarters
New York
Business Address
509 MADISON AVE. - SUITE 306, NEW YORK, NY 10022
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001430306
About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. It engages in developing and manufacturing new pharmaceutical products that are used in central nervous system drugs in large and growing markets. It products include TNX-102 SL and TNX-201. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, develops medicines for common disorders of the central nervous system. The company's lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, a Phase III clinical stage for the treatment of PTSD; and Phase II clinical stage for the treatment of military-related PTSD. The company also develops TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading